MCID: TNN002
MIFTS: 35

Tinea Unguium

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Tinea Unguium

MalaCards integrated aliases for Tinea Unguium:

Name: Tinea Unguium 12 15 71 32
Cellulitis and Abscess of Upper Arm and Forearm 12
Cellulitis and Abscess of Finger and Toe 12
Cellulitis and Abscess of Gluteal Region 12
Cellulitis and Abscess of Buttock 12
Onychomycosis Due to Dermatophyte 12
Cellulitis and Abscess of Finger 12
Cellulitis and Abscess of Trunk 12
Cellulitis and Abscess of Face 12
Dermatophytic Onychomycosis 12
Dermatophytosis of Nail 12
Cellulitis and Abscess 12
Dermatophytic Onychia 12
Onychomycosis 71

Classifications:



External Ids:

Disease Ontology 12 DOID:13074
ICD9CM 34 681.9
ICD10 32 B35.1
UMLS 71 C0007644 C0040261 C4048550

Summaries for Tinea Unguium

Disease Ontology : 12 A dermatophytosis that results in fungal infection located in nail, has material basis in Ascomycota fungi that belong to a group called dermatophytes, which cause separation of the nail plate from the nail bed and has symptom thickening of subungueal area. Sometimes, white islands are seen on the external nail plates. These gradually coalesce until the entire nail plate is involved.

MalaCards based summary : Tinea Unguium, also known as cellulitis and abscess of upper arm and forearm, is related to dermatophytosis and dermatomycosis, and has symptoms including thickening of subungueal area An important gene associated with Tinea Unguium is STAT1 (Signal Transducer And Activator Of Transcription 1). The drugs Tazarotene and Ciclopirox have been mentioned in the context of this disorder. Affiliated tissues include nail, testes and skin.

Wikipedia : 74 Onychomycosis, also known as tinea unguium, is a fungal infection of the nail. Symptoms may include... more...

Related Diseases for Tinea Unguium

Diseases related to Tinea Unguium via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 129, show less)
# Related Disease Score Top Affiliating Genes
1 dermatophytosis 31.4 SQLE FLNA CBSL B4GALNT2
2 dermatomycosis 31.1 CBSL B4GALNT2
3 tinea capitis 30.8 SQLE CBSL B4GALNT2
4 tinea pedis 30.7 SQLE MSRA CBSL B4GALNT2
5 fungal infectious disease 30.3 STAT1 CRP CBSL B4GALNT2
6 tinea corporis 30.0 SQLE FLNA CBSL B4GALNT2
7 uvulitis 10.5
8 cellulitis 10.4
9 emphysematous cholecystitis 10.3 GPT CRP
10 ascending cholangitis 10.3 GPT CRP
11 ankylosing spondylitis 1 10.3 GPT CRP
12 splenic abscess 10.3 GPT CRP
13 critical illness polyneuropathy 10.3 GPT CRP
14 acalculous cholecystitis 10.3 GPT CRP
15 white piedra 10.3 CBSL B4GALNT2
16 tinea manuum 10.3 CBSL B4GALNT2
17 otomycosis 10.3 CBSL B4GALNT2
18 granulomatous hepatitis 10.3 GPT CRP
19 viral laryngitis 10.3 GPT CRP
20 trichosporonosis 10.3 CBSL B4GALNT2
21 acute cholangitis 10.3 GPT CRP
22 cholecystolithiasis 10.3 GPT CRP
23 eumycotic mycetoma 10.3 CBSL B4GALNT2
24 heart aneurysm 10.3 GPT CRP
25 coronary aneurysm 10.3 GPT CRP
26 splenic infarction 10.3 GPT CRP
27 phaeohyphomycosis 10.3 CBSL B4GALNT2
28 abdominal tuberculosis 10.3 GPT CRP
29 paralytic ileus 10.3 GPT CRP
30 48,xyyy 10.3
31 hydrops of gallbladder 10.3 GPT CRP
32 common bile duct disease 10.3 GPT CRP
33 pyuria 10.3 GPT CRP
34 pityriasis versicolor 10.3 SQLE CBSL
35 subcutaneous mycosis 10.3 CBSL B4GALNT2
36 kwashiorkor 10.3 GPT CRP
37 analbuminemia 10.3 GPT CRP
38 volvulus of midgut 10.3 GPT CRP
39 hypopyon 10.3 CRP B4GALNT2
40 superficial mycosis 10.3 CBSL B4GALNT2
41 leprosy 3 10.3
42 erythema multiforme 10.3
43 allergic hypersensitivity disease 10.3
44 paronychia 10.3
45 urticaria 10.3
46 keratosis 10.3
47 neuritis 10.3
48 human immunodeficiency virus infectious disease 10.3
49 bullous pemphigoid 10.3
50 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids 10.3
51 hansen's disease 10.3
52 anuria 10.2 GPT CRP
53 intestinal perforation 10.2 GPT CRP
54 nasopharyngitis 10.2 GPT CRP
55 pharyngitis 10.2 GPT CRP
56 drug allergy 10.2 GPT CRP
57 mucormycosis 10.2 CRP B4GALNT2
58 compartment syndrome 10.2 GPT CRP
59 cecal disease 10.2 GPT CRP
60 bronchopneumonia 10.2 GPT CRP
61 orbital cellulitis 10.2
62 choledocholithiasis 10.2 GPT CRP
63 acute myocarditis 10.2 STAT1 CRP
64 anaerobic meningitis 10.1 FLNA CRP
65 aspiration pneumonia 10.1 GPT CRP
66 tonsillitis 10.1
67 diarrhea 10.1
68 nail disease 10.1
69 skeletal tuberculosis 10.1 FLNA CRP
70 vitamin metabolic disorder 10.1 CRP CBSL
71 primary systemic mycosis 10.1 CRP CBSL
72 louse-borne relapsing fever 10.1 CRP ARSI
73 capillary lymphangioma 10.1 FLNA CRP
74 severe acute respiratory syndrome 10.1 STAT1 GPT CRP
75 interval angle-closure glaucoma 10.1 FLNA CRP
76 late congenital syphilis 10.1 FLNA CRP
77 plasma protein metabolism disease 10.1 GPT CRP
78 marginal corneal ulcer 10.1 FLNA CRP
79 diencephalic neoplasm 10.1 UNK FLNA
80 subungual glomus tumor 10.1 FLNA CRP
81 chickenpox 10.1 STAT1 CRP
82 opportunistic mycosis 10.1 STAT1 CRP B4GALNT2
83 xerophthalmia 10.1 CRP ARSI
84 pericardium disease 10.1 GPT CRP
85 suppurative otitis media 10.1 FLNA CRP
86 hemorrhoid 10.1 FLNA CRP
87 vaginal discharge 10.1 FLNA CRP
88 dacryoadenitis 10.1
89 dacryocystitis 10.1
90 scrub typhus 10.1 GPT CRP
91 leishmaniasis 10.0 STAT1 GPT CRP
92 inherited metabolic disorder 10.0 GPT CRP CBSL
93 otitis externa 10.0 CRP CBSL B4GALNT2
94 acute pyelonephritis 10.0 GPT CRP
95 atelosteogenesis 10.0 FLNA ARSI
96 pulmonary artery disease 10.0 GPT CRP
97 exophthalmos 9.9 FLNA CRP
98 conidiobolomycosis 9.9 FLNA CBSL B4GALNT2
99 splenic disease 9.9 GPT CRP
100 retinal detachment 9.8
101 strabismus 9.8
102 kearns-sayre syndrome 9.8
103 yemenite deaf-blind hypopigmentation syndrome 9.8
104 crohn's colitis 9.8
105 sialadenitis 9.8
106 corneal edema 9.8
107 acute dacryocystitis 9.8
108 branch retinal artery occlusion 9.8
109 central retinal artery occlusion 9.8
110 uveitis 9.8
111 hidradenitis suppurativa 9.8
112 hidradenitis 9.8
113 scleredema adultorum 9.8
114 retinal artery occlusion 9.8
115 impetigo 9.8
116 crohn's disease 9.8
117 chorioretinitis 9.8
118 mechanical strabismus 9.8
119 iridocyclitis 9.8
120 fasciitis 9.8
121 necrotizing fasciitis 9.8
122 back pain 9.8
123 constipation 9.8 GPT FLNA CRP
124 apnea, obstructive sleep 9.7 GPT CRP
125 tinea cruris 9.7 SQLE FLNA CBSL B4GALNT2
126 external ear disease 9.7 UNK CRP CBSL B4GALNT2
127 thrombocytopenia 9.6 STAT1 GPT FLNA CRP
128 intestinal obstruction 9.5 MSRA GPT FLNA CRP
129 noonan syndrome 1 9.4 TRIR SUB1 GPT CBSL

Graphical network of the top 20 diseases related to Tinea Unguium:



Diseases related to Tinea Unguium

Symptoms & Phenotypes for Tinea Unguium

Symptoms:

12 (showing 1, show less)
  • thickening of subungueal area

Drugs & Therapeutics for Tinea Unguium

Drugs for Tinea Unguium (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 64, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
2
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
3
Amorolfine Approved, Investigational Phase 4 78613-35-1
4
carbamide peroxide Approved Phase 4 124-43-6
5
Tavaborole Approved, Investigational Phase 4 174671-46-6
6
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
7
Bifonazole Approved, Investigational Phase 4 60628-96-8 2378
8
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965 14956
9
Dimethyl sulfoxide Approved, Vet_approved Phase 4 67-68-5 679
10
Efinaconazole Approved Phase 4 164650-44-6
11 Dermatologic Agents Phase 4
12 Keratolytic Agents Phase 4
13 Pharmaceutical Solutions Phase 4
14 Cytochrome P-450 Enzyme Inhibitors Phase 4
15 Hormone Antagonists Phase 4
16 Hormones Phase 4
17 Cytochrome P-450 CYP3A Inhibitors Phase 4
18
Hydroxyitraconazole Phase 4
19 Anti-Bacterial Agents Phase 4
20 Antiprotozoal Agents Phase 4
21 Antiparasitic Agents Phase 4
22 Amebicides Phase 4
23 Antioxidants Phase 4
24 Protective Agents Phase 4
25 Liposomal amphotericin B Phase 4
26
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
27
Luliconazole Approved Phase 2, Phase 3 187164-19-8
28
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
29
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
30
Econazole Approved Phase 2 27220-47-9 3198
31
Isotretinoin Approved Phase 2 4759-48-2 5282379 5538
32
Naftifine Approved Phase 2 65472-88-0 47641 73342
33
Aminolevulinic acid Approved Phase 2 106-60-5 137
34
Posaconazole Approved, Investigational, Vet_approved Phase 2 171228-49-2 147912
35
Diclofenac Approved, Vet_approved Phase 2 15307-86-5 3033
36
Ethanol Approved Phase 2 64-17-5 702
37
Polihexanide Approved, Investigational Phase 2 28757-47-3
38 Albaconazole Investigational Phase 2 187949-02-6
39 Antifungal Agents Phase 2
40 Immunosuppressive Agents Phase 2
41 Immunologic Factors Phase 2
42 Benzonidazole Phase 2
43 Anti-Infective Agents, Local Phase 2
44 Analgesics, Non-Narcotic Phase 2
45 Analgesics Phase 2
46 Cyclooxygenase Inhibitors Phase 2
47 Anti-Inflammatory Agents Phase 2
48 Antirheumatic Agents Phase 2
49 Anti-Inflammatory Agents, Non-Steroidal Phase 2
50 Anti-Infective Agents Phase 2
51 Hypoglycemic Agents Phase 2
52 Disinfectants Phase 2
53 Biguanides Phase 2
54
Ketoconazole Approved, Investigational Phase 1 65277-42-1 47576
55 Tin Fluorides Phase 1
56
Methylene blue Approved, Investigational 61-73-4
57
Petrolatum Approved, Investigational Early Phase 1 8009-03-8
58
Voriconazole Approved 137234-62-9 71616
59
Creatine Approved, Investigational, Nutraceutical 57-00-1 586
60 Tea
61 Tea Tree
62 English Lavender
63 Photosensitizing Agents
64
Tea tree oil Experimental, Nutraceutical 68647-73-4

Interventional clinical trials:

(showing 127, show less)
# Name Status NCT ID Phase Drugs
1 A Multicentre, Randomized, Controlled Study of the Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer Alone for the Treatment of Dermatophytic Onychomycosis (Toenail) Without Matrix Involvement Unknown status NCT01014637 Phase 4 Amorolfine (Antifungal);RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
2 Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis Unknown status NCT02436291 Phase 4
3 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
4 A Prospective, Double-blind, Placebo-controlled Trial of Topical Penlac Nail Lacquer for Therapy of Onychomycosis in Children Completed NCT01419847 Phase 4 Ciclopirox;Placebo
5 A Multicenter, Open Label, Single-arm Study Evaluating the Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis of the Toenails Completed NCT02812771 Phase 4 Efinaconazole
6 Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish Completed NCT03110029 Phase 4 Efinaconazole 10% Topical Application Solution [JUBLIA]
7 A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment Completed NCT02464826 Phase 4 Nailprotex
8 Efficacy of Topical Resin Lacquer, Amorolfine, and Oral Terbinafine for Treating Toenail Onychomycosis: a Prospective, Randomized, Controlled, Investigator-blinded, Parallel-group Clinical Trial Completed NCT01851590 Phase 4 Amorolfine;Terbinafine
9 Change in SCIO (Scoring Clinical Index For Onychomycosis) in Toenail Onychomycosis Treating With Itraconazole Capsules Completed NCT00871728 Phase 4 Itraconazole
10 An Investigator Initiated Pilot Study Evaluating the Efficacy of Efinaconazole 10% Solution (Jublia) for the Treatment of Onychomycosis With Dermatophytomas Completed NCT03098615 Phase 4 Jublia (Efinaconazole 10% Topical Solution)
11 Subject Adherence and Satisfaction for Treatment of Onychomycosis With Loceryl Nail Lacquer 5% Versus Ciclopirox Nail Lacquer Completed NCT02679911 Phase 4 Loceryl NL;Ciclopirox NL
12 Subject Adherence and Satisfaction for Treatment of Onychomycosis With Loceryl Nail Lacquer 5% Versus a Fungal Nail Treatment Set Containing Urea 40% Ointment and Bifonazole Cream 1% Completed NCT02705664 Phase 4 Loceryl Nail Lacquer;Urea Ointment;Bifonazole Cream
13 Determination of Antifungal Activity of Loceryl Nail Lacquer 5% When Used Concomitantly With a Cosmetic Nail Varnish Compared to a Loceryl Nail Lacquer (NL) 5% Alone in Treatment of Toenail Distal Subungual Onychomycosis Completed NCT02321098 Phase 4 Loceryl NL + Cosmetic varnish;Loceryl NL 12 weeks;Loceryl NL 15 months
14 An Open-label Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Kerydin (Registered) (Tavaborole) Topical Solution, 5% In The Treatment Of Onychomycosis Of The Toenail In Pediatric Subjects Ages 6 To 16 Years And 11 Months Completed NCT03405818 Phase 4 Tavaborole 5% Topical Solution
15 Comparison of the Efficacy and Safety Between Long-pulsed Nd:YAG, Amorolfine and Combination of Long-pulsed Nd:YAG and Amorolfine in Treating Non-dermatophyte and Mixed-infection Onychomycosis Recruiting NCT02812043 Phase 4 Amorolfine
16 Comparison of Effectiveness of Topical Amphotericin B in 30% Dimethylsulphoxide and 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis: Randomized Double Blind Controlled Trial Pilot Study Recruiting NCT03814343 Phase 4 amphotericin B in 30% DMSO;30% DMSO
17 A Multicenter, Open-label, Non-controlled, Single-arm Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis Active, not recruiting NCT03280927 Phase 4 Jublia®
18 Comparative Study of Systemic Antifungal Drugs Used in Treatment of Onychomycosis Unknown status NCT03171584 Phase 3 Terbinafine
19 Treating Onychomychosis Unknown status NCT00776464 Phase 2, Phase 3
20 Study Efficacy and Safety in Comparative Use of Investigational Product Adjuvant Treatment in Onychomycosis Unknown status NCT02961634 Phase 3 Ciclopirox 8%
21 A Randomized, Double-blind, Vehicle- and Placebo-Controlled, Multicenter Trial in Patients With Mild to Moderate Distal Subungual Toenail Onychomycosis to Investigate the Efficacy, Tolerability, and Safety of Twice Daily Application of TDT 067 for 48 Weeks Unknown status NCT01145807 Phase 3 TDT067;Placebo;Transfersome
22 A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00443898 Phase 3 terbinafine;Placebo;terbinafine;Placebo
23 A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00443820 Phase 3 terbinafine;Placebo;terbinafine;Placebo
24 A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults Completed NCT01302119 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
25 A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults Completed NCT01270971 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
26 A Randomized, Open-label, Active-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride (HCl) Formulation Versus 5% Amorolfine Nail Lacquer for 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00459537 Phase 3 terbinafine hydrogen chloride;amorolfine nail lacquer
27 A Multicenter, Randomized, Double-blind, Parallel, Vehicle-controlled Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Onychomycosis Completed NCT02549001 Phase 3 P-3058 10%;vehicle of P-3058 10%;amorolfine 5%
28 Multicentre, Open Label Study to Assess the Tolerability of P-3058 Nail Solution in Paediatric Patients Affected by Mild-to-moderate Onychomycosis Completed NCT02547701 Phase 3 P-3058
29 Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis Completed NCT01008033 Phase 3 IDP-108;Vehicle
30 The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis Completed NCT01007708 Phase 3 IDP-108;Vehicle
31 Safety and Efficacy of Luliconazole Solution, 10% With Two Dosing Regimens in Distal Subungual Onychomycosis of the Toenails: A Randomized, Double-Blind, Vehicle-Controlled, Phase 2B/3 Study Completed NCT01431820 Phase 2, Phase 3 Luliconazole Solution, 10%;Vehicle Solution
32 A Phase III Randomized, Evaluator-Blind, Parallel Group Study of the Safety and Efficacy of Itraconazole Tablets, Itraconazole Capsules and Placebo in the Treatment of Onychomycosis of the Toenail. Completed NCT00356915 Phase 3 Itraconazole 100mg capsules;Itraconazole 200mg tablets;Placebo tablets
33 Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients Completed NCT03168841 Phase 3 Efinaconazole Topical
34 A Double-blind, Randomized, Multicenter, Placebo- Controlled Phase 3 Trial to Prove the Superiority of Bifonazole vs. Placebo After 4 Weeks of Onychomycosis Treatment/ as a Follow-up of a 2 Weeks Treatment of Non-surgical Nail Ablation of Diseased Nail Matrix With 40% Urea Paste Completed NCT00781820 Phase 3 Bifonazole cream 1%;Placebo cream
35 Multi-Center Trial: Evaluation of PinPointe FootLaser Treatment for Infected Toenails (Onychomycosis) Completed NCT00935649 Phase 2, Phase 3
36 A Multi-centre, Randomized, Two-armed, Parallel Group and Evaluator-blinded Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) Active, not recruiting NCT02866032 Phase 3 MOB015B;Ciclopirox 80 mg/g
37 A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) Active, not recruiting NCT02859519 Phase 3 MOB015B;MOB015B Vehicle
38 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Wks Terminated NCT01208168 Phase 3 NAB001;Vehicle alone
39 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Weeks Terminated NCT01208129 Phase 3 NAB001;Placebo control
40 A Multicenter, Randomized, Double-blind, Parallel, Vehicle-controlled Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Onychomycosis Withdrawn NCT03094468 Phase 3 P-3058 (terbinafine hydrochloride 10%);Vehicle of P-3058
41 The Efficacy of CELEXT07 in the Treatment of Toenail Onychomycosis: a Phase 2, Randomized, Double-blind Study Unknown status NCT02644551 Phase 2 CELEXT07;Penlac
42 Noveon Laser Treatment of Onychomycosis: A Device Performance Clinical Study Unknown status NCT00771732 Phase 2
43 A Phase II Trial of the Safety, Local Tolerability, and Efficacy of EcoNail™ (Econazole 5%/SEPA® 18% Nail Lacquer) in Onychomycosis of the Great Toenail Unknown status NCT00385502 Phase 2 EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)
44 AVALIAÇÃO DO USO DO LASER ERBIUM-DOPED YTTRIUM ALUMINIUM GARNET (Er:YAG) ASSOCIADO AO ESMALTE DE AMOROLFINA NO TRATAMENTO DA ONICOMICOSE Unknown status NCT01528813 Phase 2 Amorolfine lacquer
45 Phase 2 Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Three Oral E1224 Dosing Regimens and Benznidazole for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease Unknown status NCT01489228 Phase 2 E1224;Benznidazole;Placebo
46 A Pilot Study to Assess The Therapeutic Effectiveness Of Isotretinoin In Preventing Recurrences In Chronic Recurrent Dermatophytosis Unknown status NCT03471455 Phase 2 Isotretinoin;Terbinafine;Itraconazole 200 mg
47 Phase IIB Efficacy and Safety Study of Four Topical Gel Formulations of Anti-Fungal Agents, MQX-5858, MQX-5859, MQX-5866, and MQX-5867, Versus Vehicle in the Treatment of Tinea Unguium. Completed NCT00253305 Phase 2 Organogel of naftifine, 2%;Organogel of terbinafine, 2%;Organogel of naftifine, 6%;Organogel of terbinafine, 6%
48 An Unblinded Clinical Trial to Evaluate the Deposition of Terbinafine in the Nail Bed After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail Completed NCT01484145 Phase 2 Terbinafine HCl
49 An Open-label, Multiple-dose Study Of The Absorption And Systemic Pharmacokinetics Of An2690 Applied As A 7.5% Solution To All Toenails Of Adult Patients With Moderate To Severe Onychomycosis Completed NCT00680160 Phase 2 AN2690
50 A Subject Blinded, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail Completed NCT01080079 Phase 2 Terbinafine Hydrochloride
51 A Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled Study of the Safety & Efficacy of HTU-520 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail Completed NCT01400594 Phase 2 HTU-520 Patch
52 A Phase 1/2a, Open-Label Study Evaluating the Pharmacokinetics, Safety and Tolerability of Luliconazole Solution, 10% in Subjects With Moderate to Severe Distal Subungual Onychomycosis Completed NCT01044381 Phase 1, Phase 2 Luliconazole Solution, 10%
53 An Open,Single-centre Pilot Study of Efficacy and Safety of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO) Completed NCT01814020 Phase 2 MOB015B
54 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Distal Lateral Subungual Onychomycosis of the Toenail Completed NCT02267356 Phase 2 VT-1161;Placebo
55 An Open, Multi-centre Trial Comparing the Efficacy and Safety of Two Different Treatment Regimens of Topical MOB015 Treatment of Distal Subungual Onychomycosis (DSO) Completed NCT01246518 Phase 2 MOB015
56 A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi- Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability Patients With Mild to Moderate Onychomycosis Completed NCT02933879 Phase 2 NVXT topical;Placebo (Vehicle) Topical
57 A Randomized, Double-Blind, Parallel-Group,Multicenter, Dose-Response, Vehicle-Controlled Study of the Safety and Efficacy of NB-002 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail Completed NCT00453271 Phase 2 NB-002;Vehicle control
58 An Open-label, Multiple-dose Study Of The Absorption And Systemic Pharmacokinetics Of An2690 Applied As A 7.5% Solution To All Toenails Of Adult Patients With Moderate To Severe Onychomycosis Completed NCT00679601 Phase 2 AN2690
59 A Phase 2 Randomized, Double-Blind, Vehicle-Controlled, Dose-Ranging Study to Investigate the Efficacy and Safety of ME1111 in Patients With Mild to Moderate Onychomycosis Completed NCT02022215 Phase 2 ME1111 Solution, Low strength;ME1111 Solution, High strength;Matching Vehicle Solution
60 Evaluation of the Suitability of PD P 506 A in the Photodynamic Therapy of Distal Subungual Onychomycosis (DSO) of the Great Toenail. Completed NCT02355899 Phase 2 PD P 506 A
61 A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis Completed NCT00777868 Phase 2 Low Strength IDP-108;High Strength IDP-108;High Strength IDP-108 under occlusion;Vehicle
62 An Open Label, Multi-center Study To Evaluate The Safety And Efficacy Of Topically Applied An2690 1% And 5% Solutions For The Treatment Of Adult Subjects With Onychomycosis Of The Great Toenail Completed NCT00680134 Phase 2 AN2690;AN2690
63 An Open-Label Phase 2 Study to Investigate the Efficacy, Tolerability, and Safety of the HTS-519 Insert in the Treatment of Subjects With Distal Lateral Subungual Onychomycosis of the Great Toenail Completed NCT02798380 Phase 2 HTS-519 Insert
64 A Phase II Open Label Multiple-Dose Study of the Safety and Pharmacokinetics of TDT 067 Under Conditions of Maximal Use in Subjects With Distal Subungual Onychomycosis of the Toenails Completed NCT01790165 Phase 2 TDT067 and Lamisil
65 An Investigator-Blinded Study Evaluating the Efficacy and Safety of Four Posaconazole Treatment Regimens With Placebo and Terbinafine in the Treatment of Onychomycosis of the Toenail Completed NCT00491764 Phase 2 SCH 56592;SCH 56592;SCH 56592;SCH 56592;Terbinafine;Placebo
66 An Open-Label, Rising Multiple-Dose, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 5.0% and 7.5% Solution for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail Completed NCT01278394 Phase 2 AN2690 Solution, 5.0%
67 A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the Efficacy and Safety of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis Completed NCT00730405 Phase 2 Albaconazole 100mg;Albaconazole 200mg;Albaconazole 400mg;Albaconazole 400mg;Placebo 400 mg
68 A Randomized, Double Blind, Multiple-site, Placebo-Controlled Study, Comparing the Efficacy and Safety of SUBA™-Itraconazole Capsules Compared to SPORANOX® (Itraconazole) Capsules in the Treatment of Onychomycosis of the Toenail Completed NCT00791219 Phase 2 SUBA-itraconazole;Itraconazole;Placebo
69 An Open-Label, Rising Multiple-Dose, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 5.0% and 7.5% Solution for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail Completed NCT00679523 Phase 2 AN2690 Solution, 5.0%;AN2690 Solution, 7.5%
70 A Randomized, Double-blind, Vehicle-controlled, Multi-center Study To Evaluate The Safety And Efficacy Of Topically Applied An2690 2.5%, 5.0%, And 7.5% Solutions Vs. Vehicle For The Treatment Of Adult Subjects With Onychomycosis Of The Great Toenail. Completed NCT00679770 Phase 2 AN2690, 2.5%;AN2690, 5%;AN2690, 7.5%;Vehicle
71 A Randomized, Double-Blind, Placebo-Controlled, Pilot Study to Assess the Safety and Efficacy of NVXT Solution in Patients With Mild-to-Moderate Fungal Infection of the Toe Nail Completed NCT02343627 Phase 2 NVXT Solution;Vehicle of test product
72 A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 2.5%, 5.0%, and 7.5% Solutions vs. Vehicle for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail Completed NCT00679965 Phase 2 AN2690, 2.5%;AN2690, 5%;AN2690, 7.5%;AN2690 Solution Vehicle
73 Dr. Bill Antifungal Nail Gel Study Recruiting NCT04341402 Phase 2 Antifungal Nail Gel Study
74 A Multi-Centre, International, Randomised, Vehicle Controlled, Parallel-Group, Double-Blinded Phase 2 Trial of BB2603 Topical Treatment in Subjects With Distal Subungual Onychomycosis (DSO) of the Toenail Not yet recruiting NCT04188574 Phase 2 BB2603-1;BB2603-3;BB2603-10;Vehicle
75 A Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TMI-358 in the Treatment of Distal Subungual Onychomycosis of the Toenail Terminated NCT01093118 Phase 2 TMI-358;MMI-467
76 Optimizing the Treatment of Toenail Onychomycosis Using a New Transdermal Patch Combined With Terbinafine and Ketoconazole Formulation Unknown status NCT01615913 Phase 1 3 mg terbinafine and 2 mg ketoconazole containing patch;6 mg terbinafine and 2 mg ketoconazole containing patch;8 mg terbinafine and 2 mg ketoconazole containing patch
77 A Study of the Systemic Absorption of Once Daily MOB015B When Applied for 28 Days in Subjects With Moderate to Severe Onychomycosis of the Toenails. Completed NCT03244280 Phase 1 MOB015B
78 A Randomized, Placebo-Controlled Study of the 1320 nm Nd:YAG Laser for Improving the Appearance of Onychomycosis Completed NCT01498393 Phase 1
79 A Phase 1 Randomized, Double-Blind, Vehicle-Controlled, Multiple-Dose Study of the Safety, Absorption and Systemic Pharmacokinetics of ME1111 Topical Agent Applied to All Toenails of Adult Moderate to Severe Onychomycosis Patients for 28 Days Completed NCT01841996 Phase 1 ME1111 solution;Vehicle Solution
80 A Single-blind Evaluation of Device Performance and Tolerability to Nail Micro-drilling in Subjects With Onychomycosis Completed NCT00941317 Phase 1
81 21-day Cumulative Irritation Test Completed NCT00680095 Phase 1 AN2690;AN2690;AN2690
82 A Double-Blind, Randomized, Parallel Design Study To Assess the Safety and Pharmacokinetics of Terbinafine Hydrogen Cloride (HCl) Nail Lacquer Applied for 28 Days in Patients With Onychomycosis Completed NCT00691184 Phase 1 Placebo;Terbinafine Hydrochloride;Terbinafine Hydrochloride;Terbinafine
83 A Phase 1, Randomized, Open-Label, Crossover Safety and Pharmacokinetic Study of 400 mg Albaconazole as a Tablet Formulation Versus a Capsule Formulation in Healthy Subjects Completed NCT01039883 Phase 1 Albaconazole tablet 400mg;Albaconazole 100mg capsules, then albaconazole 400mg tablet
84 A Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Tolerability And Pharmacokinetic Study Of Escalating Doses Of Albaconazole In Healthy Subjects Completed NCT01014962 Phase 1 Albaconozole;Placebo;Albaconozole;Placebo;Albaconozole;Placebo
85 A Study of Skin/Nail Sensation and the Pharmacokinetics of the Uptake of Terbinafine in the Great Toe Nail and Systemically Following Treatment With the Electrokinetic Transungual System (ETS)-Terbinafine Gel in Healthy Normal Voluneteers Completed NCT00768768 Phase 1
86 A Multi-Center Pilot Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Plasma Treatment System in Improving the Appearance of Onychomycosis Unknown status NCT02724384
87 A Randomized, Parallel-Group, Multicentre, Open-Labelled, Active-Controlled Study to Assess the Efficacy, Safety and Tolerability of RV4104A Ointment Versus Bifonazole-Urea Ointment for the Complete Removal of the Clinically Infected Nail Plate Area in Patients With Toenail Onychomycosis Unknown status NCT00808366 Keratolytic/Antifungal;Keratolytic/Antifungal
88 Comparison of Efficacy and Safety Between Methylene Blue-mediated Photodynamic Therapy and 5% Amorolfine Nail Lacquer for Toenail Onychomycosis Treatment in Asians Unknown status NCT03098342 Amorolfine 5% Nail Lacquer
89 Demonstration of the Spread of Dermatophytes Through Casual Contact Among Family Household Members Unknown status NCT00233493
90 A Randomized Study to Evaluate the Efficacy of Herbal Ingredients Combined With a Carrier System (Phytonail) Compared With Amorolfine 5% Nail Lacquer (Loceryl) in the Treatment of Toenail Onychomycosis Unknown status NCT01929187 Phytonail;Loceryl
91 A Randomized Controlled Study to Assess the Impact of Dermatology Consultations on the Hospital Course of Patients Admitted for Cellulitis Unknown status NCT01706913
92 Evaluation of an Oligonucleotide Array for Rapid Identification of Dermatophytes in Clinical Specimens Completed NCT02270697
93 Study of the V-Raser Diode Laser System in the Treatment of Onychomycosis Completed NCT01452490
94 A Clinical Investigation on Early Visible Effects of Application of K101 During 8 Weeks on Discoloured and Deformed Nails Resulting From Onychomycosis Completed NCT01180491
95 A Single Center, Pilot Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Plasma Treatment System in Treating Onychomycosis Completed NCT01819051
96 Clinical Evaluation of Efficacy and Safety of a Medical Device for the Treatment of Toenail Onychomycosis. Completed NCT03382717 Loceryl 5%
97 Clinical Evaluation of the Efficacy of a Medical Device in Treatment of Toenail Onychomycosis Completed NCT03289871 Loceryl 5%
98 Pulsed Dye Laser Treatment of Onychomycosis Completed NCT01915355
99 Onychomycosis: Diagnosis and Prevalence in Diabetic Neuropathic Patients Completed NCT00525187
100 Clinical Trial of Safety and Efficacy of Topical ABL01 Treatment of Onychomycosis Completed NCT03141840
101 Evaluation of the Efficacy of Chesson Labs LIQUICURE™ for Treatment of Onychomycosis Completed NCT00960089
102 Prevalence and Clinical Characteristics of the Fungal Nail and Feet Infection in Patients With Hallux Valgus Completed NCT02464839
103 A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of 250 mg Terbinafine Hydrochloride Tablets Under Fasting Conditions Completed NCT00602342 Terbinafine
104 A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of 250 mg Terbinafine Hydrochloride Tablets Under Fed Conditions Completed NCT00602251 Terbinafine
105 A Clinical Investigation to Evaluate the Safety and Performance of a Treatment Kit for Ingrowing Toenail Completed NCT02131363
106 A Single Centre Retrospective Chart Review Study to Assess the Efficacy of the GenesisPlus 1064 nm Nd:YAG Laser in the Treatment of Onychomycosis Completed NCT02445495
107 An Evaluation of the Effect of the Erchonia FX-405™ on Treating Toenail Onychomycosis Clinical Study Completed NCT01534689
108 An Evaluation of the Effect of the Erchonia LUNULA on Treating Toenail Onychomycosis Completed NCT02242019
109 Treatment of Onychomycosis Using a 0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser Completed NCT01666002
110 Laser Therapy for Onychomycosis in Patients Wih Diabetes at Risk for Diabetic Foot Complications Completed NCT01996995
111 A Retrospective Evaluation of the Effect of the Erchonia LUNULA™ on the Increase of Clear Nail in Patients With Toenail Onychomycosis Completed NCT02588599
112 A Single Center Open Label Early Feasibility Study to Evaluate the Efficacy and Safety of the RenewalNail™ Plasma Treatment System in Patients With Mild to Moderate Onychomycosis (Fungal Nail) of the Hallux Caused by Trichophyton Rubrum or Trichophyton Mentagrophytes. Completed NCT03216200
113 A Prospective, Open Label, Non-comparative Clinical Investigation to Evaluate the Performance of a Fungal Nail Treatment on the Visual Signs of Onychomycosis Completed NCT02546258
114 A Multi Center Open Label Early Feasibility Study to Evaluate the Efficacy and Safety of the RenewalNail™ Plasma Treatment System in Patients With Mild to Moderate Onychomycosis (Fungal Nail) of the Hallux Caused by Trichophyton Rubrum or Trichophyton Mentagrophytes. Completed NCT03072550
115 A Pilot Study Investigating Antitumorigenic Potential of Topical Itraconazole in the Treatment of Basal Cell Carcinoma Completed NCT02120677 Early Phase 1 Itraconazole
116 Evaluation of the Efficacy of Anti-mold Azole Prophylaxis in High-risk Hematologic Patients With Baseline Superficial Skin Lesions Positive for Fusarium Spp Completed NCT02714504 Voriconazole or posaconazole
117 A Randomized-controlled Study to Assess the Impact of Dermatology Consultations on Reducing Admissions for Patients Presenting to Internal Medicine Clinics for Possible Cellulitis Completed NCT01795092
118 An Internet Mediated Research Study to Assess the Quality of Life of Consumers With Self-reported Fungal Nail Infection (Onychomycosis) During Treatment With Scholl Fungal Nail. Recruiting NCT04084782
119 A Pilot Evaluation of the Effect of the Erchonia LunulaLaser for the Treatment of Toenail Onychomycosis Recruiting NCT03066336
120 Safety and Efficacy of Next Science Wound Gel in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO): An Open-Label Pilot Study Recruiting NCT04042857
121 Prevalence and Risk Evaluation of Diabetic Complications of the Foot in A Large Canadian Population Recruiting NCT04327622
122 Blue Light Photodynamic Therapy Treatment for Distal and Lateral Subungual Toenail Onychomycosis Active, not recruiting NCT03022903
123 Evaluating the Effectiveness of Laser Treatment for Onychomycosis of the Hallux in Patients With Diabetes: A Randomized Controlled Trial Not yet recruiting NCT02019446 Standard Treatment (control group) terbinafine hydrochloride tablets
124 Usefulness of White Blood Cell Count (WBCC) During Infection: a Comparison Between Hospitalized Geriatric and Young Groups. Not yet recruiting NCT03943277
125 Subclinical Nail Involvement in Relevant Skin Diseases Not yet recruiting NCT04092413
126 A Placebo Controlled, Randomized, Prospective Study to Evaluate the Efficacy and Safety of PinPointe FootLaser in Patients Who Have Failed Oral Terbinafine Treatment for Onychomycosis Terminated NCT01920178
127 Effectiveness of Supplementation With Nail Debridement in Ungual Lacquer Treatment in Podiatry Care on Onychomycosis: Pilot Study of Randomized Control Trial Withdrawn NCT00938925

Search NIH Clinical Center for Tinea Unguium

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ciclopirox
Ciclopirox olamine
Itraconazole
tavaborole
terbinafine
Terbinafine hydrochloride

Genetic Tests for Tinea Unguium

Anatomical Context for Tinea Unguium

The Foundational Model of Anatomy Ontology organs/tissues related to Tinea Unguium:

19
Nail

MalaCards organs/tissues related to Tinea Unguium:

40
Testes, Skin

Publications for Tinea Unguium

Articles related to Tinea Unguium:

(showing 276, show less)
# Title Authors PMID Year
1
Epidemiological survey of 42 403 dermatophytosis cases examined at Nagasaki University Hospital from 1966 to 2015. 61
32293052 2020
2
Whole-genome resequencing of Trichophyton rubrum provides insights into population differentiation and drug resistance. 61
31538279 2020
3
Skin Infections and Outpatient Burn Management: Fungal and Viral Skin Infections. 61
31995350 2020
4
Molecular identification of isolates of the Trichophyton mentagrophytes complex. 61
31929737 2020
5
Epidemiology of dermatophytic infections between 2008 and 2017 in Barcelona, Spain. 61
31076176 2019
6
Tinea unguium caused by terbinafine-resistant Trichophyton rubrum successfully treated with fosravuconazole. 61
31353607 2019
7
In search of the source of dermatophytosis: Epidemiological analysis of Trichophyton verrucosum infection in llamas and the breeder (case report). 61
31538413 2019
8
Internal environment of footwear is a risk factor for tinea pedis. 61
31436337 2019
9
Epidemiology of dermatophytosis in northeastern Iran; A subtropical region. 61
31321333 2019
10
Terbinafine-resistant strain of Trichophyton interdigitale strain isolated from a tinea pedis patient. 61
30768808 2019
11
Differences Between Patient-Reported Versus Clinician-Observed Nonulcerative Signs and Symptoms of the Foot in Patients With Diabetes Mellitus. 61
30747799 2019
12
Characteristics and Efficacy of Two Topical Therapeutic Agents for Onychomycosis. 61
31474693 2019
13
Detection of Trichophyton rubrum and Trichophyton interdigitale in onychomycosis using monoclonal antibodies against Sub6 (Tri r 2). 61
30152879 2019
14
2016 Epidemiological Survey of Dermatomycoses in Japan. 61
31474694 2019
15
Epidemiological and clinical aspects of dermatophytoses in Eastern Slovakia: a retrospective three-year study. 61
30817878 2018
16
Ultrastructural changes of Trichophyton rubrum in tinea unguium after itraconazole therapy in vivo observed using scanning electron microscopy. 61
30387190 2018
17
Molecular Epidemiological Analysis of the Spreading Conditions of Trichophyton in Long-Term Care Facilities in Japan. 61
30175735 2018
18
Topical efinaconazole: A promising therapeutic medication for tinea unguium. 61
30035311 2018
19
Tinea unguium onychomycosis caused by dermatophytes: a ten-year (2005-2014) retrospective study in a tertiary hospital in Singapore. 61
29552686 2018
20
Epidemiology of dermatophytoses in 31 municipalities of the province of Buenos Aires, Argentina: A 6-year study. 61
29606407 2018
21
Characterizing the clinical isolates of dermatophytes in Hamadan city, Central west of Iran, using PCR-RLFP method. 61
29439839 2018
22
Subungual Amelanotic Melanoma Masquerading as Onychomycosis. 61
29755903 2018
23
Common Child and Adolescent Cutaneous Infestations and Fungal Infections. 61
29198783 2018
24
Comment on "Prevalence, Etiology, and Risk Factors of Tinea Pedis and Tinea Unguium in Tunisia". 61
29849837 2018
25
Response to: Comment on "Prevalence, Etiology, and Risk Factors of Tinea Pedis and Tinea Unguium in Tunisia". 61
29951161 2018
26
Recurrent dermatophytosis: A rising problem in Sikkim, a Himalayan state of India. 61
29323069 2017
27
High prevalence of superficial white onychomycosis by Trichophyton interdigitale in a Japanese nursing home with a geriatric hospital. 61
28436564 2017
28
Epidemiology of dermatomycoses in Kerman province, southeast of Iran: A 10-years retrospective study (2004-2014). 61
28757272 2017
29
Pathogenic Dermatophytes Survive in Nail Lesions During Oral Terbinafine Treatment for Tinea Unguium. 61
28281037 2017
30
Examining the accuracy of visual diagnosis of tinea pedis and tinea unguium in aged care facilities. 61
28379097 2017
31
Epidemiological status of dermatophytosis in Guilan, north of Iran. 61
29302626 2017
32
New Antifungal Agents and New Formulations Against Dermatophytes. 61
27502503 2017
33
Tinea Unguium: Diagnosis and Treatment in Practice. 61
27787643 2017
34
Dermatophyte Antigen Kit. 61
28566667 2017
35
[Affinity of Luliconazole for Human Nail Derived Keratin]. 61
29187718 2017
36
Prevalence, Etiology, and Risk Factors of Tinea Pedis and Tinea Unguium in Tunisia. 61
28852411 2017
37
Characterization of clinically important dermatophytes in North of Iran using PCR-RFLP on ITS region. 61
27496524 2016
38
Is the Dermatophyte Test Strip truly useful for the diagnosis of tinea unguium? Inquiry into "Clinical study of Dermatophyte Test Strip, an immunochromatographic method, to detect tinea unguium dermatophytes". 61
27910169 2016
39
[Causative agents of superficial mycoses isolated in Dakar, Senegal: Retrospective study from 2011 to 2015]. 61
27592054 2016
40
[Tinea unguium with Microsporum langeronii and Trichophyton soudanense revealing tinea capitis with M. langeronii]. 61
27592053 2016
41
Clinical study of Dermatophyte Test Strip, an immunochromatographic method, to detect tinea unguium dermatophytes. 61
26992478 2016
42
Production of an anti-dermatophyte monoclonal antibody and its application: immunochromatographic detection of dermatophytes. 61
27250927 2016
43
Identification of three yeast species using the conventional and internal transcribed spacer region sequencing methods as first or second global record from human superficial infections. 61
27392537 2016
44
Protocol for the systematic review of the prevention, treatment and public health management of impetigo, scabies and fungal skin infections in resource-limited settings. 61
27659511 2016
45
Epidemiological Aspects of Dermatophytosis in Khuzestan, southwestern Iran, an Update. 61
26886443 2016
46
Epidemiology of Superficial Fungal Infections in Guangdong, Southern China: A Retrospective Study from 2004 to 2014. 61
26883512 2016
47
[Superficial mycoses: casuistry of the Mycology Department of the Instituto Nacional de Higiene "Rafael Rangel", Caracas, Venezuela (2001-2014)]. 61
27382801 2016
48
Molecular Characterization and In Vitro Antifungal Susceptibility of 316 Clinical Isolates of Dermatophytes in Iran. 61
26369643 2016
49
Development and Evaluation of a Novel Real-Time PCR for Pan-Dermatophyte Detection in Nail Specimens. 61
26412381 2016
50
[Affinity of Luliconazole to Keratin Prepared from Healthy Human Nailand Porcine Hoof]. 61
26936352 2016
51
Computational analysis of conserved coil functional residues in the mitochondrial genomic sequences of dermatophytes. 61
28149055 2016
52
Oral Antifungal Drugs in the Treatment of Dermatomycosis. 61
27251319 2016
53
Epidemiology of Dermatophytoses in Crete, Greece. 61
27904054 2016
54
A survey of the etiological agents of scalp and nail dermatophytosis in Yazd, Iran in 2014-2015. 61
28680997 2015
55
Tinea corporis due to Trichophyton violaceum: A report of two cases. 61
26470976 2015
56
Pattern of Dermatophytes in Patients Attend in Mymensingh Medical College Hospital. 61
26620004 2015
57
Dermatophytosis in patients with human immunodeficiency virus infection: clinical aspects and etiologic agents. 61
26200786 2015
58
Screening for tinea unguium by thermography in older adults with subungual hyperkeratosis. 61
25311983 2015
59
Dermatophytosis: a 16-year retrospective study in a metropolitan area in southern Brazil. 61
26322879 2015
60
Dermatophytes and other associated fungi in patients attending to some hospitals in Egypt. 61
26413063 2015
61
Tinea capitis in schoolchildren in a rural area in southern Ethiopia. 61
25557908 2015
62
Case of dermatophyte abscess caused by Trichophyton rubrum: a case report and review of the literature. 61
25786380 2015
63
Diagnostic accuracy of tinea unguium based on clinical observation. 61
25545551 2015
64
Prevalence of Dermatophytic Infection and the Spectrum of Dermatophytes in Patients Attending a Tertiary Hospital in Addis Ababa, Ethiopia. 61
26448763 2015
65
Spectrum of dermatophyte infections in Botswana. 61
25834462 2015
66
Evaluation of a commercial PCR test for the diagnosis of dermatophyte nail infections. 61
25418736 2015
67
[2011 Epidemiological Survey of Dermatomycoses in Japan]. 61
26617109 2015
68
Topical therapy for toenail onychomycosis: an evidence-based review. 61
25257931 2014
69
Diagnosis and management of tinea infections. 61
25403034 2014
70
Candida galli as a cause of tinea unguium-molecular characterization of a rare clinical fungal entity. 61
25037486 2014
71
Mycology - an update part 2: dermatomycoses: clinical picture and diagnostics. 61
25176455 2014
72
The role of topical antifungal therapy for onychomycosis and the emergence of newer agents. 61
25053979 2014
73
[Mycological profile of onychomycosis in Dakar (Senegal)]. 61
24631372 2014
74
Dermatophytosis and immunovirological status of HIV-infected and AIDS patients from Sao Paulo city, Brazil. 61
24417711 2014
75
[Infections of finger and toe nails due to fungi and bacteria]. 61
24718510 2014
76
The prevalence of skin eruptions and mycoses of the buttocks and feet in aged care facility residents: a cross-sectional study. 61
24192312 2014
77
[Trichophyton thuringiense H.A. Koch 1969. A rare geophilic dermatophyte--now isolated for the first time from man]. 61
24531767 2014
78
Screening for tinea unguium by Dermatophyte Test Strip. 61
24117339 2014
79
A retrospective cohort study of tinea pedis and tinea unguium in inpatients in a psychiatric hospital. 61
24943206 2014
80
The Prevalence and Pattern of Superficial Fungal Infections among School Children in Ile-Ife, South-Western Nigeria. 61
25574161 2014
81
Psychosocial impact of onychomycosis: a review. 61
24164152 2013
82
A clinicomycological study of cutaneous mycoses in sawai man singh hospital of jaipur, north India. 61
24380015 2013
83
Surveillance of dermatophytosis in northeast of Iran (Mashhad) and review of published studies. 61
23943426 2013
84
A Molecular Epidemiological Survey of Clinically Important Dermatophytes in Iran Based on Specific RFLP Profiles of Beta-tubulin Gene. 61
26060667 2013
85
Onychomycosis in children: an experience of 59 cases. 61
24003276 2013
86
Dermatophytes isolated from superficial fungal infections in Krakow, Poland, between 1995 and 2010. 61
23346893 2013
87
[Molecular biological detection of dermatophytes in clinical samples when onychomycosis or tinea pedis is suspected. A prospective study comparing conventional dermatomycological diagnostics and polymerase chain reaction]. 61
23532505 2013
88
Rapid real-time diagnostic PCR for Trichophyton rubrum and Trichophyton mentagrophytes in patients with tinea unguium and tinea pedis using specific fluorescent probes. 61
23287391 2013
89
Molecular epidemiology of dermatophytosis in Tehran, Iran, a clinical and microbial survey. 61
22587730 2013
90
Mating type gene (MAT1-1) in Japanese isolates of Trichophyton rubrum. 61
23212652 2013
91
Distribution and species composition of causative agents of dermatophytoses in Lithuania. 61
24001417 2013
92
Epidemiological aspects of Trichophyton rubrum var. raubitschekii in Japan. 61
22900925 2012
93
Stability of tandemly repetitive subelement PCR patterns in Trichophyton rubrum over serial passaging and with respect to drug pressure. 61
22814817 2012
94
Epidemiology of dermatophytoses: retrospective analysis from 2005 to 2010 and comparison with previous data from 1975. 61
22707134 2012
95
[2006 Epidemiological survey of dermatomycoses in Japan]. 61
23149353 2012
96
[Scanning electron microscopic observation on the parasitic form of the fungi in the horny layer in dermatophytosis]. 61
22728594 2012
97
Animal model of dermatophytosis. 61
22619489 2012
98
Tinea capitis and tinea corporis with a severe inflammatory response due to Trichophyton tonsurans. 61
21710105 2011
99
Disseminated erythema multiforme-like reaction triggered by tinea unguium. 61
21554422 2011
100
Changes of dermatophytoses in southwestern Greece: an 18-year survey. 61
21331751 2011
101
Prevalence of dermatological disorders in Japan: a nationwide, cross-sectional, seasonal, multicenter, hospital-based study. 61
21426384 2011
102
Molecular analysis and mating behaviour of the Trichophyton mentagrophytes species complex. 61
20708436 2011
103
[Tinea unguium]. 61
21788720 2011
104
Optimized 5-hour multiplex PCR test for the detection of tinea unguium: performance in a routine PCR laboratory. 61
20105101 2010
105
Superficial fungal infections seen at a tertiary health centre: clinical and mycological studies. 61
20931516 2010
106
Community dermatology in Debre Markos: an attempt to define children's dermatological needs in a rural area of Ethiopia. 61
20618472 2010
107
Dynamics of dermatophytosis frequency in Mexico: an analysis of 2084 cases. 61
19886762 2010
108
Epidemiological survey of foot diseases in Japan: results of 30,000 foot checks by dermatologists. 61
20536644 2010
109
[Dermatophytoses due to anthropophilic fungi in Cadiz, Spain, between 1997 and 2008]. 61
20398600 2010
110
Commentary: the illusory tinea unguium cure. 61
20159309 2010
111
[Tricophyton rubrum in a case of tinea unguium phenotypic mycological diagnostic algorithm and its limits]. 61
21038705 2010
112
Dermatophytes in Republic of Macedonia. 61
20693949 2010
113
Prevalence of tinea pedis, tinea unguium of toenails and tinea capitis in school children from Barcelona. 61
19766517 2009
114
Efficacy of fluconazole for the treatment of onychomycosis. 61
19776299 2009
115
[Antimycotic therapy of Tinea unguium and other onychomycoses]. 61
19777736 2009
116
Cutaneous fungal infections in the United States: Analysis of the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS), 1995-2004. 61
19570075 2009
117
Dermatophyte infections in Cairo, Egypt. 61
18972221 2009
118
[Dermatophytosis: a summary of dermatomycosis as a proposal for future revision of the guidelines]. 61
19942789 2009
119
Preventing long term relapsing tinea unguium with topical anti-fungal cream: a case report. 61
19154619 2009
120
[Dermatomycosis--classification, etiology, pathogenesis, and treatment]. 61
19069093 2008
121
Update in antifungal therapy of dermatophytosis. 61
18478357 2008
122
Dermatophyte infections in patients attending a tertiary care hospital in northern Italy. 61
19123311 2008
123
Double-blind clinical trial for evaluating the effectiveness and tolerability of Ageratina pichinchensis extract on patients with mild to moderate onychomycosis. A comparative study with ciclopirox. 61
18671197 2008
124
Preanalytical conditions for broth microdilution antifungal susceptibility of Microsporum spp. 61
18422920 2008
125
Itraconazole concentrations of fingernails and toenails of patients with tinea unguium. 61
18477237 2008
126
Common tinea infections in children. 61
18533375 2008
127
Dermatophytoses in outpatients attending the Dermatology Center of Avicenna Hospital in Qazvin, Iran. 61
18254753 2008
128
A 7-year survey of dermatophytoses in Crete, Greece. 61
17944710 2007
129
In vitro antifungal susceptibility patterns of dermatophyte strains causing tinea unguium. 61
17714532 2007
130
Twelve cases of tinea unguium in a pediatric clinic in 9 years. 61
17123110 2007
131
Tinea pedis and tinea unguium in a 7-year-old child. 61
17644724 2007
132
Tinea unguium in the north-west of Iran (1996-2004). 61
17604428 2007
133
Species distribution and antifungal susceptibilities of dermatophytes during a one year period at a university hospital in Turkey. 61
17305776 2007
134
Tinea faciei incognito due to Trichophyton rubrum as a result of autoinoculation from onychomycosis. 61
17681050 2007
135
Dermatophytoses in monterrey, méxico. 61
16466445 2006
136
[Statistical study of dermatomycosis - observations in Sendai National Hospital over a 30 year period]. 61
16465134 2006
137
[An epidemiological survey of dermatomycoses in Japan, 2002]. 61
16699491 2006
138
[Comparative study between culture and PCR-RFLP analysis on identification of the causative agent of Tinea Unguium]. 61
16465135 2006
139
[A case of onychomycosis induced by Scopulariopsis brevicaulis]. 61
16699490 2006
140
Epidemiology of tinea pedis and toenail tinea unguium in worshippers in the mosques in Adana, Turkey. 61
16361711 2005
141
First report on autochthonous urease-positive Trichophyton rubrum (T. raubitschekii) from South-east Europe. 61
16029346 2005
142
[Study on patient satisfaction with the treatment of mycosis on the extremities with terbinafine (SETTA)]. 61
16476388 2005
143
[Superficial mycoses: comparative study between type 2 diabetic patients and a non-diabetic control group]. 61
15782538 2005
144
Origins of onychomycosis. 61
15450895 2004
145
Photodynamic treatment of the dermatophyte Trichophyton rubrum and its microconidia with porphyrin photosensitizers. 61
15244503 2004
146
Mucocutaneous lesions in transplant recipient in a tropical country. 61
15518786 2004
147
Pedal dermatophyte infection in psoriasis. 61
15214898 2004
148
Onychomycosis caused by an isolate conforming to the description of Trichophyton raubitschekii. 61
15283242 2004
149
Frequency and risk factors of dermatophytosis in students living in rural areas in Eskişehir, Turkey. 61
15281399 2004
150
Etiologic agents of dermatophyte infection in Lebanon. 61
15884683 2004
151
Onychomycosis caused by Fusarium solani and Fusarium oxysporum in São Paulo, Brazil. 61
15180157 2004
152
Prevalence and risk factors for superficial fungal infections among Italian Navy Cadets. 61
15459531 2004
153
[Statistical study of dermatomycosis for 30 years (1968-1997) in sendai national hospital]. 61
15284829 2004
154
[Epidemiological survey of dermatophytosis in Spain (April-June 2001)]. 61
14572379 2003
155
Dermatophyte agents in the city of São Paulo, from 1992 to 2002. 61
14743665 2003
156
An epidemiological and clinical study of untreated patients with tinea pedis within a company in Japan. 61
12801364 2003
157
Clinical and mycological study of occult tinea pedis and tinea unguium in dermatological patients from Tokyo. 61
12870199 2003
158
Characteristics of superficial mycoses in Malta. 61
12694490 2003
159
Epidemiology of dermatophytoses in an area south of Tehran, Iran. 61
14682452 2003
160
[Prevalence of zoophilic dermatophytes in the Sarajevo region]. 61
12822383 2003
161
Cutaneous infections in the elderly: diagnosis and management. 61
14510876 2003
162
[Analysis of dermatophyte flora at a private clinic in Sapporo during the period 1992 to 2001]. 61
12913811 2003
163
[Prevalence and patient's consciousness of tinea pedis and onychomycosis]. 61
14615789 2003
164
[Immune response in dermatophytosis]. 61
14615793 2003
165
[Diagnosis of dermatophytoses: conventional methods and recent molecular biological methods]. 61
14615790 2003
166
Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine. 61
12435679 2002
167
Experimental tinea unguium model to assess topical antifungal agents using the infected human nail with dermatophyte in vitro. 61
12525893 2002
168
A survey of skin disease among patients in an Australian nursing home. 61
12395875 2002
169
Clinical variations in dermatophytosis in HIV infected patients. 61
17656940 2002
170
[Clinical and epidemiological survey of dermatophytoses in Jaen (Spain)] 61
12716229 2002
171
[Dermatophyte flora at the dermatology clinic of Kimitsu Chuo Hospital from 1994 through 1999]. 61
11865297 2002
172
[Diversified treatments of Tinea unguium]. 61
12040365 2002
173
Smear positive leprosy with HIV infection, silent neuritis and extensive tinea corporis and tinea unguium in an Indian male. 61
11898467 2001
174
Role of oral antifungal agents for the treatment of superficial fungal infections in immunocompromised patients. 61
11499333 2001
175
Common viral and fungal skin infections. 61
11890082 2001
176
Utility of inoculum counting (Walshe and English criteria) in clinical diagnosis of onychomycosis caused by nondermatophytic filamentous fungi. 61
11376044 2001
177
Tinea unguium in Lahore, Pakistan. 61
11346265 2001
178
[Epidemiologic characteristics of onychomycosis--results of a retrospective study]. 61
11759211 2001
179
Dermatophytoses in children: study of 137 cases. 61
11340481 2001
180
Interferon-gamma production in peripheral lymphocytes of patients with tinea pedis: comparison of patients with and without tinea unguium. 61
11270412 2001
181
Urease-positive Trichophyton rubrum strains (previously described as T. raubitschekii): first isolations in Argentina. 61
12188013 2001
182
[1997 Epidemiological survey of dermatophytoses in Japan]. 61
11173330 2001
183
[Treatment of tinea unguium with terbinafine: an open study comparing twelve weeks and twenty-four weeks of continuous terbinafine therapy, and determination of terbinafine level in the target nails]. 61
11704757 2001
184
[Observation of tinea unguium by neutral red staining]. 61
11479534 2001
185
Asthma, rhinitis and dermatitis triggered by fungal infection: therapeutic effects of terbinafine. 61
11455147 2001
186
Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. 61
11051137 2000
187
Prevalence and risk factors of tinea unguium and tinea pedis in the general population in Spain. 61
10970362 2000
188
Mycotic infections. Effective management of conditions involving the skin, hair, and nails. 61
10826264 2000
189
Foot complications in people with diabetes: a community-based study in Taiwan. 61
10743340 2000
190
[Dermatophytosis of the external auditory meatus]. 61
10938522 2000
191
[1996 epidemiological survey of dermatophytoses in Japan. Epidemiological Investigation Committee for Human Mycoses in the Japanese Society for Medical Mycology]. 61
10938521 2000
192
[On the epidemiology of dermatophytoses in Granada (Andalousia, Spain).]. 61
18473602 1999
193
Management of onychomycoses. 61
10473020 1999
194
Superficial fungal infections in children and adolescents. 61
10542582 1999
195
[Dermatophytes isolated in Hospital Universitario 12 de Octubre (Madrid, Spain).]. 61
18473578 1999
196
Dermal patches for the controlled release of miconazole: influence of the drug concentration on the technological characteristics. 61
10219539 1999
197
Clinical and mycological features of dermatophytosis in renal transplant recipients. 61
10394853 1999
198
A review of the epidemiology of tinea unguium in the community. 61
10098282 1999
199
Current topics in diagnosis and treatment of tinea unguium in Japan. 61
10091478 1999
200
[Evaluation of the efficacy of small-dose itraconazole pulse therapy (200 mg/day) for tinea unguium]. 61
9929581 1999
201
Prevalence of dermatophytoses in the Zarqa district of Jordan. 61
10685449 1999
202
Itraconazole oral solution for the treatment of onychomycosis. 61
9875972 1998
203
[Tinea unguium--onychomycosis. Quality Assurance Committee of the German Society of Dermatology and the Professional Organization of German Dermatologists e. V]. 61
9866039 1998
204
[Oral terbinafine for the tinea unguium of the toenails. Efficacy between 12 and 24 weeks of treament.]. 61
18473539 1998
205
Diagnosis and management of common tinea infections. 61
9672436 1998
206
Skin and wound infections: an overview. 61
9614412 1998
207
An overview of topical antifungal therapy in dermatomycoses. A North American perspective. 61
9585862 1998
208
Demonstration of dermatophyte dissemination from the infected soles using the foot-press method. 61
9670767 1998
209
[Topical treatment of onychomycosis by occlusive dressing using bifonazole cream containing 40% urea]. 61
9487003 1998
210
[Two cases of dermatophytosis of the external auditory meatus]. 61
9580035 1998
211
[Dermatophytes isolated in our clinics. 5-year-study in Zaragoza]. 61
9580210 1997
212
Toenail onychomycosis in patients with acquired immune deficiency syndrome: treatment with terbinafine. 61
9390334 1997
213
There is something wrong with my nail. 61
9197054 1997
214
[Etiologic and epidemiologic study of dermatomycoses in Navarra (Spain)]. 61
16854174 1997
215
Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy. The Lagos V Study Group. 61
9205509 1997
216
Epidemiology and ecology of onychomycosis. 61
9154399 1997
217
Unusual Microsporum canis infections in adult HIV patients. 61
8912591 1996
218
Treatment of onychomycosis and tinea pedis with intermittent itraconazole therapy. 61
8936929 1996
219
German randomized double-blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. 61
8763463 1996
220
Levels of fluconazole in normal and diseased nails during and after treatment of onychomycoses in toe-nails with fluconazole 150 mg once weekly. 61
8800303 1996
221
Onychomycosis in Rome, Italy. 61
9144955 1996
222
Tinea pedis in members of the Japanese Self-defence Forces: relationships of its prevalence and its severity with length of military service and width of interdigital spaces. 61
8720203 1995
223
Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group. 61
7580551 1995
224
Dermatology. 61
7752408 1995
225
Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium. German Collaborative Dermatophyte Drug Susceptibility Study Group. 61
7625820 1995
226
Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. 61
7722020 1995
227
Short therapy for tinea unguium with terbinafine: four different courses of treatment. 61
8531933 1995
228
The proteolytic activity of strains of T. mentagrophytes and T. rubrum isolated from tinea pedis and tinea unguium infections. 61
7666296 1995
229
Skin manifestations associated with rheumatoid arthritis. 61
7673550 1995
230
Dermatophytosis in northern Greece during the decade 1981-1990. 61
7477093 1995
231
Clinical and pharmacokinetic investigations of oral terbinafine in patients with tinea unguium. 61
7477090 1995
232
Dermatophytoses in Mexico City. 61
7935593 1994
233
Dermatophytoses in Iran. 61
7935592 1994
234
Pharmacokinetic optimisation of oral antifungal therapy. 61
8261715 1993
235
Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. 61
8257124 1993
236
Down syndrome, alopecia universalis, and trachyonychia. 61
8346118 1993
237
Atopic dermatitis associated with dermatophyte infection and Trichophyton hypersensitivity. 61
8444052 1993
238
KONCPA: a new method for diagnosing tinea unguium. 61
8219416 1993
239
[The reaction to trichophytin in dermatophytoses]. 61
1342118 1992
240
New antifungal agents. 61
1327600 1992
241
Dermatophytosis of children in Kuwait. 61
1574472 1992
242
Is tinea unguium still widely incurable? A review three decades after the introduction of griseofulvin. 61
1531407 1992
243
Scytalidium hyalinum isolated from the toe nail of an Australian patient. 61
1303078 1992
244
Hendersonula toruloidea and Scytalidium hyalinum. Review and update. 61
2064405 1991
245
Dermatophytoses in Cusco (Peru). 61
1749399 1991
246
Review of dermatophytoses in Galicia from 1951 to 1987, and comparison with other areas of Spain. 61
2034261 1991
247
Itraconazole in dermatophyte infections: clinical experience in Italy. 61
1965414 1990
248
Itraconazole in common dermatophyte infections of the skin: fixed treatment schedules. 61
2170473 1990
249
[Onychomycosis. Clinico-epidemiological mycological and therapeutic aspects]. 61
2143740 1990
250
[Dermatomycoses observed at the Dermatologic Clinic, Pavia University. 2) Pathology of Microsporum gypseum]. 61
2365400 1990
251
[Treatment of tinea unguium]. 61
2533696 1989
252
Aetiology of onychomycosis and tinea unguium. 61
2530843 1989
253
Skin and oral mucosal changes in patients infected with human immunodeficiency virus. 61
2461031 1988
254
Tinea unguium. 61
2960495 1987
255
A modified method to detect dermatophytes in the diagnosis of tinea unguium. 61
2961845 1987
256
A modified method for rapid mycological diagnosis of Tinea unguium in Taiwan, Republic of China. 61
2954779 1987
257
Tinea unguium. 61
2946867 1986
258
Non-surgical (physicochemical) Nail Removal and Antifungal Therapy of Tinea Unguium. 61
28150612 1986
259
Urea plaster for softening diseased nails in the treatment of tinea unguium. 61
2962190 1986
260
Incidence of dermatophytosis in Jordan with special reference to tinea capitis. 61
4069193 1985
261
Epidemiological trends of dermatophytoses and dermatophytes in Jerusalem between 1954 and 1981. 61
4010765 1985
262
Superficial Mycoses in Simla. 61
28176743 1983
263
New data on the epidemiology of Tinea cruris in Israel. 61
6669165 1983
264
[New therapy of tinea unguium: ODT (occlusive dressing technic) using 20% urea ointment and an antifungal agent]. 61
6217362 1982
265
[Surgical treatment of tinea unguium combined with administration of griseofulvin and vasoactive drugs]. 61
6107956 1980
266
Incidence of dermatophytes in the San Francisco Bay area. 61
7398991 1980
267
[Value of the method of surgical removal of the nails in combined treatment of tinea unguium and cutaneous moniliasis]. 61
160591 1979
268
A study of 3891 cases of mycoses in the tropics. 61
134458 1976
269
Tinea capitis in Pondicherry (South India). 61
123659 1975
270
Trichophyton rubrum infections according to age, anatomical distribution and sex. 61
125094 1975
271
[Thearpy of tinea unguium and results of follow-up examinations since the introduction of griseofulvin]. 61
123314 1975
272
Dermatophytic agents of tinea unguium in Iran. 61
4270580 1973
273
[Therapy of tinea unguium]. 61
4238989 1967
274
[STUDIES ON TINEA UNGUIUM. I. RELATIONSHIP BETWEEN THE SPECIES OF DERMATOPHYTES AND THE CLINICAL MANIFESTATION]. 61
14170260 1964
275
The effects of griseofulvin on tinea unguium. 61
13734747 1960
276
Tinea Unguium. 61
20476404 1953

Variations for Tinea Unguium

ClinVar genetic disease variations for Tinea Unguium:

6 (showing 1, show less) ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 STAT1 NM_007315.3(STAT1):c.821G>A (p.Arg274Gln)SNV Pathogenic 30085 rs387906760 2:191859910-191859910 2:190995184-190995184

Expression for Tinea Unguium

Search GEO for disease gene expression data for Tinea Unguium.

Pathways for Tinea Unguium

GO Terms for Tinea Unguium

Sources for Tinea Unguium

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....